Experience at Son Espases University Hospital with daratumumab, bortezomib, lenalidomide and dexamethasone (D-VRd) as first line treatment in multiple myeloma

被引：0
|
作者：
Monsonis, Lola Piquer [1 ]
Sampalo, Maria Gali [1 ]
Montana, Albert Perez [1 ]
Raga, Jose Maria Sanchez [1 ]
Mayol, Antonia Sampol [1 ]
机构：
[1] Hosp Univ Son Espases, Palma De Mallorca, Spain
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P158
引用
收藏
页码：S122 / S122
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma
    Narsipur, Nihal
    Bulla, Sabrina
    Yoo, Connie
    Do, Brenda
    Tran, Kyle
    Gu, Dian
    Zhong, Lixian
    Wilson, Leslie
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (12): : 1691 - 1702
  • [32] Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
    Nadeem, Omar
    Magidson, Sophie
    Redd, Robert A.
    Laubach, Jacob
    Mo, Clifton C.
    O'Donnell, Elizabeth K.
    Sperling, Adam S.
    Hartley-Brown, Monique A.
    Midha, Shonali
    Marto, Marjorie
    Davie, Christine
    Ricciardi, Caroline
    Choden, Dechen
    Strutevant, Ashlee
    Alberti, Jillian
    Trippa, Lorenzo
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Ghobrial, Irene M.
    BLOOD, 2023, 142
  • [33] Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
    Voorhees, Peter M.
    Kaufman, Jonathan L.
    Laubach, Jacob
    Sborov, Douglas W.
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Silbermann, Rebecca
    Costa, Luciano J.
    Anderson, Larry D., Jr.
    Nathwani, Nitya
    Shah, Nina
    Efebera, Yvonne A.
    Holstein, Sarah A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Murphy, Sean
    Lutska, Yana
    Pei, Huiling
    Ukropec, Jon
    Vermeulen, Jessica
    de Boer, Carla
    Hoehn, Daniela
    Lin, Thomas S.
    Richardson, Paul G.
    BLOOD, 2020, 136 (08) : 936 - 945
  • [34] BORTEZOMIB IN THE FIRST-LINE TREATMENT OF MULTIPLE MYELOMA: THE EXPERIENCE OF A CENTER
    Mendes, M. J.
    Ferreira, G.
    Saturnino, H.
    Duarte, M.
    Almeida, J. C.
    Arajo, L. F.
    Ribeiro, M. L.
    HAEMATOLOGICA, 2015, 100 : 735 - 735
  • [35] Isatuximab-carfilzomib-dexamethasone immediately after failing of the quadruplet Daratumumab-bortezomib-lenalidomide-dexamethasone (Dara-VRD): Striking response with no washout in a newly diagnosed multiple myeloma
    Gil-Fernandez, Juan Jose
    Ramirez, Patricia Garcia
    Charavia, Marta Callejas
    CLINICAL CASE REPORTS, 2024, 12 (01):
  • [36] Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse
    Montefusco, Vittorio
    Corso, Alessandro
    Galli, Monica
    Ardoino, Ilaria
    Pezzatti, Sara
    Carniti, Cristina
    Patriarca, Francesca
    Gherlinzoni, Filippo
    Zambello, Renato
    Sammassimo, Simona
    Marcatti, Magda
    Nozza, Andrea
    Crippa, Claudia
    Cafro, Anna Maria
    Baldini, Luca
    Corradini, Paolo
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (06) : 907 - 917
  • [37] Indirect Treatment Comparisons of Daratumumab, Pomalidomide, and Dexamethasone Versus Daratumumab, Bortezomib, and Dexamethasone or Bortezomib and Dexamethasone in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
    He, Jianming
    Berringer, Heather
    Heeg, Bart
    Kampfenkel, Tobias
    Dwarakanathan, Harikumaran R.
    Johnston, Stephen
    Mendes, Joao
    Lam, Annette
    Bathija, Sacheeta
    Mackay, Eric
    BLOOD, 2021, 138
  • [38] Race Is Associated with Bortezomib but Not Lenalidomide Utilization during First-Line Treatment of Multiple Myeloma
    Fiala, Mark A.
    Ailawadhi, Sikander
    Vij, Ravi
    Wildes, Tanya M.
    BLOOD, 2017, 130
  • [39] A NON-INTERVENTIONAL OBSERVATIONAL RETROSPECTIVE STUDY OF SECOND-LINE TREATMENT WITH THE COMBINATION DARATUMUMAB - BORTEZOMIB - DEXAMETHASONE (DARAVD) IN MULTIPLE MYELOMA PATIENTS REFRACTORY TO LENALIDOMIDE
    Rizzello, I.
    Zamagni, E.
    Solli, V.
    Poletti, A.
    Tacchetti, P.
    Pantani, L.
    Mancuso, K.
    Rocchi, S.
    De Cicco, G.
    Fusco, A.
    Ursi, M.
    Barbato, S.
    Terragna, C.
    Martello, M.
    Testoni, N.
    Marzocchi, G.
    Cavo, M.
    HAEMATOLOGICA, 2021, 106 (10) : 167 - 168
  • [40] First Line Therapy in Multiple Myeloma: VAD vs Bortezomib -Dexamethasone
    Borsi, Ema-Cristina
    Bucur, Adina
    Oncu, Cristina Potre
    Oncu, Ovidiu Potre
    Cerbu, Bianca
    Costachescu, Dan
    Ionita, Ioana
    Luca, Constantin Tudor
    Ionita, Hortensia
    REVISTA DE CHIMIE, 2019, 70 (03): : 1017 - 1022
12345